Ribonucleoside-diphosphate reductase subunit M2 (RRM2) could promote proliferation and chemotherapy resistance of NSCLC cells via upregulating epidermal growth factor receptor expression and AKT phosphorylation (Huang et al., 2019). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.